Please assess the completion status of the following clinical trial:

Trial Title: Prehospital Analgesia With Intra-Nasal Ketamine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients who have an acute painful condition, as determined by the Emergency Health Services attendant~* A pain score of 5 or greater (signifying moderate or severe pain)~* Desire for analgesia when queried.~Exclusion Criteria:~* Less than 18 years of age.~* Previous hypersensitivity, intolerance or allergy to ketamine~* Chest pain~* Altered mental status~* Inability self-report pain score~* Pregnancy~* Nasal occlusion~* Systolic Blood Pressure \< 90 mm Hg~* Requiring immediate attention of the paramedic~* Ineligible to receive inhaled nitrous oxide as per BC EHS protocols

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intranasal Ketamine (Type: EXPERIMENTAL): Ketamine dosing will be weight-based as follows: 30mg of IN ketamine for patients weighing 50 kg or less; 50 mg of IN ketamine for patients weighing 50 kg to 100 kg; and 75 mg of IN ketamine for patients weighing greater than 100 kg (i.e. 0.5 mg/kg to 1.0 mg/kg of intranasal ketamine). Syringes containing ketamine will be prepared from the intravenous formulation of Ketamine (50 mg / ml) solution (Sandoz; DIN 02246796) and stored in pre-filled 5 ml syringes. Ketamine will be administered to patients through a mucosal atomization device. One-half of the pre-specified volume will be administered into each nare. No repeat doses will be administered.
- Placebo (Type: PLACEBO_COMPARATOR): Syringes containing normal saline will be prepared such that the volume of normal saline in 5 ml syringes matches that of the ketamine for each of the weight based groups previously specified in the Treatment Arm Description. Syringes containing normal saline will also be labeled Study Drug. The normal saline will also be administered to patients through a mucosal atomization device. One-half of the pre-specified volume will be administered into each nare. No repeat doses of placebo will be administered.

Based on this trial design, predict the completion outcome and termination type (if applicable).